RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Losing weight by dieting (restricting energy) includes, along with fat loss, losing lean mass, about half of which is ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

They also can help lower blood sugar and protect heart health. The drugs work in different ways in the body to cause these ...